基本信息
views: 6
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
He received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002; and is an active member of the American Society for Clinical Investigation and the American Pediatric Society.
RESEARCH
The Scharenberg laboratory is focused on the development of technology for engineering T-cells and hematopoetic stem cells:
1. Gene editing methods and technology: Our present efforts are centered on optimizing gene editing efficiency in primary T-cells and hematopoietic stem cells using viral vectors and advanced electroporation methods, and on developing gene edited cell products for hematopoietic genetic diseases and tolerance applications.
2. Synthetic biology: Next generation cell therapies require new approaches to provide physician control over cell survival, expansion, and potency. We are working on developing orthogonal receptor signaling systems that can be embedded in gene edited cell products to enable precise control over these characteristics.
3. Vector biology: we are working on developing synthetic vector systems for delivery of gene therapy and gene editing components both ex vivo and in vivo.
RESEARCH
The Scharenberg laboratory is focused on the development of technology for engineering T-cells and hematopoetic stem cells:
1. Gene editing methods and technology: Our present efforts are centered on optimizing gene editing efficiency in primary T-cells and hematopoietic stem cells using viral vectors and advanced electroporation methods, and on developing gene edited cell products for hematopoietic genetic diseases and tolerance applications.
2. Synthetic biology: Next generation cell therapies require new approaches to provide physician control over cell survival, expansion, and potency. We are working on developing orthogonal receptor signaling systems that can be embedded in gene edited cell products to enable precise control over these characteristics.
3. Vector biology: we are working on developing synthetic vector systems for delivery of gene therapy and gene editing components both ex vivo and in vivo.
Research Interests
Papers共 252 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
A. Yingst,D. Vereide, D. Jarrell,R. Koning, C. Arnold, A. Romanov, M. Murphy,R. Crisman, R.P. Larson, B. Salinas,A. Scharenberg, S. O'Hara
Cytotherapyno. 6 (2024): S17
Christopher J. Nicolai, Maura Parker,Jim Qin, Weiliang Tang, Justin Ulrich-Lewis, Rebecca J. Gottschalk, Sara Cooper,Susana Hernandez,Don Parrilla, Richard Mangio, Nolan Ericson,Alissa Brandes,
Blood (2024)
CANCER RESEARCHno. 7 (2023)
MOLECULAR THERAPYno. 4 (2023): 99-100
Cited0Views0Bibtex
0
0
crossref(2023)
Peter J. Cook,Su Jung Yang, Gene I. Uenishi, Annaiz Grimm,Samuel E. West,Li-Jie Wang, Chester Jacobs, Andrea Repele, Travis Drow, Ahmad Boukhris,Noelle P. Dahl, Karen Sommer,
Molecular therapy : the journal of the American Society of Gene Therapyno. 8 (2023): 2472-2488
Alyssa Sheih, Nanda Coelho,Kathryn Michels,Anna Ting,Susana H. Lopez,Kelsey Lynch,Kristen Mittelsteadt, Ruth Chenault,Alissa Brandes,Don Parrilla,Anai M. Perez,Mason Muhonen,
MOLECULAR THERAPYno. 4 (2023): 27-28
Cited0Views0Bibtex
0
0
Maura Parker, Justin Ulrich-Lewis, Weiliang Tang,Chris Nicolai,Kathryn Michels,Susana Hernandez,Don Parrilla, Sara Cooper,Anai Perez,Mollie McDonnell,Greyson Hamilton,Chang-Chih Wu,
Blood (2023): 765
crossref(2023)
Load More
Author Statistics
#Papers: 0
#Citation: 0
H-Index: 0
G-Index: 0
Sociability: 0
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn